Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2008

View Archived Issues

Amgen presents results from a phase II study of AMG-108 in RA patients

Trial data show beneficial effects of epratuzumab in systemic lupus erythematosus

Atrasentan-liposomal doxorubicin combination feasible in platinum-resistant ovarian cancer

Nanocort safe in rheumatoid arthritis patients

ITF-2357 affects disease activity in systemic onset juvenile idiopathic arthritis

Esreboxetine improves pain, function and fatigue in double-blind fibromyalgia study

Athersys achieves development milestone in Bristol-Myers discovery alliance

Duska and DSM enter manufacturing collaboration for ATPace

Medtronic acquires CryoCath Technologies

Clinical data on CP-690550 in rheumatoid arthritis accumulates

AMG-623 characterized in phase I studies in systemic lupus erythematosus patients

FDA accepts TheraQuest's IND for abuse deterrent opioid TQ-1015

Novel compounds for lipoprotein disorders described in recent patents

Genetic Immunity doses first patient in phase II DermaVir Patch trial for HIV

Sygnis receives European orphan drug status for AX-200 in spinal cord injury

New antidiabetic agents disclosed in recent patent literature

GSK and Janssen patents divulge new therapeutics for GI disorders

Recent patent literature reports new oncolytic agents

Daiichi Sankyo commences phase III anti-influenza CS-8958 trial

FDA approves Banzel as adjunctive treatment for Lennox-Gastaut syndrome

Vernalis presents an update on clinical activities between July and November 2008

Third quarter highlights at AEterna Zentaris

Pfizer launches independent research unit Pfizer Regenerative Medicine

New glycine transporter GlyT1 inhibitor profiled at Merck & Co.

Merck Eprova imparts new PET imaging agents in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...